As many as one in three people will experience a neurological disorder in their lifetime, yet over 70% of cognitive declines occur asymptomatically before an official diagnosis is ever made. While traditional cognitive tests only capture a snapshot of mental performance at a single moment, a new approach is entering the market. Swiss neurotech startup Connectome Health has announced a $2 million funding round led by Redstone, with participation from Concept Ventures, Octopus, and business angels from both sides of the Atlantic.
Founded in 2024 by Lucas Scherdel and Dr. Rufus Mitchell-Heggs, the project is built on continuous, longitudinal tracking of brain activity. The startup’s technology stems from research conducted at Imperial College London, which demonstrated that daily behaviors leave measurable traces in cerebral blood flow. By leveraging this, the platform builds personalized patient profiles, making it easier to spot early red flags for issues such as burnout, ADHD, or the onset of dementia.
Connectome Health’s edge over hardware-centric solutions like Muse headbands or Kernel technology lies in its focus on contextual interpretation. The tool doesn’t just collect neural signals because it goes way further. System integrates signals with data on sleep, activity levels, and behavioral load and answers the “why” behind changes in a user’s cognitive function by bridging the gap between raw medical data and the context of daily life.
The fresh capital will be used to deploy the product with select partners and further fuel R&D. Co-founder Lucas Scherdel emphasizes that cognitive health is declining quietly but noticeably on a massive scale, with symptoms like brain fog and attention issues increasingly affecting younger generations. Swiss tech aims to move beyond the wearables market and to play a critical role in the world of neurological diagnostics.